Zongqiong Sun1, Xiaofang Cheng2, Yuxi Ge1, Lin Shao1, Yinghua Xuan3, Gen Yan4. 1. Department of Radiology, Affiliated Hospital, Jiangnan University, Wuxi, People's Republic of China. 2. Department of Radiology, Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital, Guangzhou, People's Republic of China. 3. Department of Basic Medicine, Jiangnan University Medical School, Wuxi, People's Republic of China. 4. Department of Radiology, Affiliated Hospital, Jiangnan University, Wuxi, People's Republic of China. gyan@stu.edu.cn.
Abstract
BACKGROUND: This study used low-dose computed tomography (CT) perfusion imaging technology to evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced gastric adenocarcinoma and to determine whether any of the perfusion parameters could predict tumor response to chemotherapy. METHODS: Forty patients with gastric adenocarcinoma (T3-4NxM0) received three cycles of neoadjuvant chemotherapy and low-dose spiral CT perfusion imaging prior to and after the first and third series of chemotherapy. We calculated tissue blood flow (BF) and blood volume (BV) using commercial software. One-way analysis of variance (ANOVA) was used to detect any significant variation of the tested parameters between different times of scanning. Spearman's test was used to evaluate the correlation among perfusion parameters, tumor size and pathological efficacy grade, and clinical response after chemotherapy, respectively. A receiver-operating characteristic analysis was used to determine the optimal diagnostic cutoff value for changes in perfusion parameters and tumor size. RESULTS: One-way ANOVA showed significant differences in BF and BV values between those before and after chemotherapy (p < 0.01). The BF, BV and size reduction rate after three series of chemotherapy were significantly correlated with pathological efficacy grade. BF and BV values after the first and third series of chemotherapy were also significantly correlated with clinical response (p < 0.01, respectively). The diagnostic sensitivity and specificity of the BV reduction rate were higher than those of size reduction rate. CONCLUSIONS: Low-dose CT perfusion imaging is a valuable tool that permits microcirculation evaluation and therefore can evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced gastric adenocarcinoma.
BACKGROUND: This study used low-dose computed tomography (CT) perfusion imaging technology to evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced gastric adenocarcinoma and to determine whether any of the perfusion parameters could predict tumor response to chemotherapy. METHODS: Forty patients with gastric adenocarcinoma (T3-4NxM0) received three cycles of neoadjuvant chemotherapy and low-dose spiral CT perfusion imaging prior to and after the first and third series of chemotherapy. We calculated tissue blood flow (BF) and blood volume (BV) using commercial software. One-way analysis of variance (ANOVA) was used to detect any significant variation of the tested parameters between different times of scanning. Spearman's test was used to evaluate the correlation among perfusion parameters, tumor size and pathological efficacy grade, and clinical response after chemotherapy, respectively. A receiver-operating characteristic analysis was used to determine the optimal diagnostic cutoff value for changes in perfusion parameters and tumor size. RESULTS: One-way ANOVA showed significant differences in BF and BV values between those before and after chemotherapy (p < 0.01). The BF, BV and size reduction rate after three series of chemotherapy were significantly correlated with pathological efficacy grade. BF and BV values after the first and third series of chemotherapy were also significantly correlated with clinical response (p < 0.01, respectively). The diagnostic sensitivity and specificity of the BV reduction rate were higher than those of size reduction rate. CONCLUSIONS: Low-dose CT perfusion imaging is a valuable tool that permits microcirculation evaluation and therefore can evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced gastric adenocarcinoma.
Authors: Priyanka Prakash; Mannudeep K Kalra; Avinash K Kambadakone; Homer Pien; Jiang Hsieh; Michael A Blake; Dushyant V Sahani Journal: Invest Radiol Date: 2010-04 Impact factor: 6.016
Authors: Ahmed E Othman; Carolin Brockmann; Zepa Yang; Changwon Kim; Saif Afat; Rastislav Pjontek; Omid Nikoubashman; Marc A Brockmann; Konstantin Nikolaou; Martin Wiesmann; Jong Hyo Kim Journal: Eur Radiol Date: 2015-05-30 Impact factor: 5.315
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Soo Jin Lee; Won Woo Lee; Hai-Jeon Yoon; Ho-Young Lee; Kyoung Ho Lee; Young Hoon Kim; Do Joong Park; Hyung-Ho Kim; Young So; Sang Eun Kim Journal: Eur J Radiol Date: 2013-02-12 Impact factor: 3.528
Authors: Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen Journal: JAMA Date: 2004-01-14 Impact factor: 56.272
Authors: Sang Min Lee; Se Hyung Kim; Jeong Min Lee; Seock-Ah Im; Yung-Jue Bang; Woo Ho Kim; Min A Kim; Han-Kwang Yang; Hyuk-Joon Lee; Won Jun Kang; Joon Koo Han; Byung Ihn Choi Journal: Abdom Imaging Date: 2009-07